



C.O.#139900

COMMISSIONERS COURT
COMMUNICATION

REFERENCE NUMBER

PAGE 1 OF 4

DATE: 12/13/2022

SUBJECT: **APPROVAL OF FIRST AMENDMENT TO THE SUBRECIPIENT AGREEMENT BETWEEN TARRANT COUNTY AND UT SOUTHWESTERN MONCRIEF CANCER CENTER, D/B/A MONCRIEF CANCER INSTITUTE FOR MOBILE PREVENTATIVE CANCER SCREENINGS AS PART OF THE TARRANT COUNTY FISCAL RECOVERY FUNDS PROGRAM**

COMMISSIONERS COURT ACTION REQUESTED

It is requested that the Commissioners Court approve the First Amendment to the Subrecipient Agreement with UT Southwestern Moncrief Cancer Center, d/b/a Moncrief Cancer Institute for mobile preventative cancer screenings as part of the Tarrant County Fiscal Recovery Funds program.

BACKGROUND

On January 18, 2022, the Commissioners Court, through Court Order #137259, approved a Subrecipient Agreement between Tarrant County and UT Southwestern Moncrief Cancer Center, d/b/a Moncrief Cancer Institute in the amount of \$9 million as part of the Tarrant County Fiscal Recovery Funds program.

Through this program, Moncrief Cancer Institute provides mobile cancer screenings and diagnostic services to unscreened patients, including historically unserved or underserved communities or individuals who delayed or have not completed a scheduled screening since the onset of the COVID-19 pandemic.

As a result of this action, funds within the original budget will be reallocated to support increased outreach efforts and to purchase a smaller mobile unit to allow greater flexibility in serving target populations. This amendment does not increase the overall award amount to UT Southwestern Moncrief Cancer Center, d/b/a Moncrief Cancer Institute.

FISCAL IMPACT

There is no fiscal impact associated with this item.

SUBMITTED BY: Administrator's Office

PREPARED BY: Russell Schaffner
APPROVED BY:



**FIRST AMENDMENT TO THE SUBRECIPIENT AGREEMENT BETWEEN
TARRANT COUNTY AND UT SOUTHWESTERN MONCRIEF CANCER CENTER
D/B/A MONCRIEF CANCER INSTITUTE**

Tarrant County ("COUNTY") and UT Southwestern Moncrief Cancer Center d/b/a Moncrief Cancer Institute ("SUBRECIPIENT"), each a "Party" and collectively the "Parties" to a Subrecipient Agreement related to the use of State and Local Fiscal Recovery Funds ("FRF") dated January 12, 2022 (the "Agreement"), now wish to amend the Agreement. This amendment is effective upon the signature of the Parties.

WHEREAS, on January 18, 2022, through Court Order No. 137259, COUNTY approved an agreement with SUBRECIPIENT; and

WHEREAS, COUNTY wishes to amend that agreement to reallocate funds to support increased outreach efforts and the purchase of a second, smaller mobile unit to increase SUBRECIPIENT's ability to reach target populations; and


WHEREAS, COUNTY and SUBRECIPIENT wish to amend that agreement to include key performance indicators to track the success of SUBRECIPIENT's increased outreach efforts.

NOW, THEREFORE, the Parties agree as follows:

1. Appendices B and C shall be modified as included herein.
2. Except as modified by this Amendment, all terms and conditions of the Agreement shall remain in effect.

SIGNED AND EXECUTED this 7th day of December, 2022.

**COUNTY OF TARRANT
STATE OF TEXAS**


B. Glen Whitley
County Judge

**UT SOUTHWESTERN MONCRIEF
CANCER CENTER D/B/A
MONCRIEF CANCER INSTITUTE**

DocuSigned by:

JAN15EF165187484
Keith Argenbright
Director

APPROVED AS TO FORM:


(Criminal District Attorney)

**CERTIFICATION OF
AVAILABLE FUNDS:** \$0.00

Tarrant County Auditor

*By law, the Criminal District Attorney's Office may only approve contracts for its clients. We reviewed this document as to form from our client's legal perspective. Other parties may not reply on this approval. Instead, those parties should seek contract review from independent counsel.

APPENDIX B
PROGRAM BUDGET/ELIGIBLE EXPENDITURES

Program Timeline: January 1, 2022 through December 31, 2024

Category	Program Budget
Personnel	1,863,903
Fringe	\$655,464
Travel	\$15,861
Equipment	\$1,047,772
Supplies	\$74,517
Clinical Services	\$4,207,193
Marketing	\$412,361
Indirect	\$722,929
Total	\$9,000,000

APPENDIX C EVALUATION MATRIX/REPORTING

Required Reporting Dates:

Quarterly Report Periods		Report Due
First	July 1- Sept 30	Oct 15
Second	Oct 1- Dec 31	Jan 15
Third	Jan 1- Mar 31	April 15
Fourth	April 1- Jun 30	July 15

Annual Report Periods		Report Due Date
Year 1	July 1- June 30, 2022	July 15, 2022
Year 2	July 1- June 30, 2023	July 15, 2023
Year 3	July 1- June 30, 2024	July 15, 2024
Year 4	July 1- June 30, 2025	July 15, 2025

UT Southwestern Moncrief Cancer Institute Program Reporting Information						
Activity Number	Activity Conducted	Time Frame for Activity	Anticipated Cost of Activity	Expected Number to be Served by each Activity	Expected Outcomes*	Intended Benefit
1	Cancer Screening through MCI	36 months	\$6 million	2,000 patients	12,000 services	Increase proportion of men and women using cancer screening guidelines established by USPTF Improve time to clinic resolution Improve lost-to-follow up rate for patients with abnormal results
2	Mobile Health Clinic	36 months	\$2 million	1,000 patients	1,000 services	Increase proportion of men and women using cancer screening guidelines established by USPTF Improve time to clinic resolution Improve lost-to-follow up rate for patients with abnormal results Improve access to geographically convenient services
3	Economic Changes	36 months	Costs included in Activities 1 and 2	3,000 patients	100%	To understand the impact of the COVID pandemic through these activities
4	Patient Navigation and Community Outreach	36 months	\$1 million in addition to costs included under Activities 1 and 2	3,000 patients 250,000 impressions	100% 2% conversion rate	Raise awareness of cancer screening and treatment Form partnerships with community organizations that enable stretching of resources